Implementing the Medicare $2 drug list model would have reduced out-of-pocket spending by 63% for Part D beneficiaries in 2021. The model caps cost-sharing at $2 for a 30-day supply of 101 generic ...
Medicare costs, such as premiums, deductibles, and copayments, are subject to annual changes. The amounts may vary based on healthcare inflation, beneficiary income, and program utilization. The ...
Differential coding by Medicare Advantage plans appeared to have pushed their risk scores higher than traditional Medicare's scores. Those greater risk scores led to $33 billion in extra revenue for ...
The Inflation Reduction Act's attempt to improve insulin costs for Medicare beneficiaries-by capping out-of-pocket costs at ...
Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost ...
Early prescription refills by U.S. pharmacies cost Medicare and patients $3B in 2021–2023, with mail-order pharmacies run by UnitedHealth (UNH) and Humana (HUM) leading the cost overruns, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results